TD Cowen says NeoGenomics is still a good buy and has raised its price target to $23.

Oct 30, 2026, 6:07 PM ETOpinionRead the original at in.tradingview.com

Good for NEO

NeoGenomics kept TD Cowen's Buy rating, and the firm raised its target from $19 per share to $23 per share. That signals greater analyst confidence, though the report gives no new company results.

NEO · NeoGenomics, Inc.

AI read · Good for NEO

The AI's read

That points to stronger confidence in NeoGenomics from this analyst. But an analyst's view is not proof that sales or profit have improved. The report includes no new company results, so the positive read rests on the higher target and continued Buy rating.

Get alerts for NEO

Follow NeoGenomics, Inc. (NEO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NEO

Free on the App Store and Google Play, or on the web.